Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study

References

• Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16
   PubMed Web of Science ®Google Scholar
• Trevisan M, Liu J, Bahsas FB, et al. Syndrome X and mortality: a population-based study. Am J Epidemiol 1998;148:958-66
   PubMed Web of Science ®Google Scholar
• Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;73:307-12
   Google Scholar
• Alexander CM, Landsman PB, Teutsch SM, et al.; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP)NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-14
   PubMed Web of Science ®Google Scholar
• The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   Google Scholar
• Athyros VG, Ganotakis ES, Elisaf M, et al. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005;21:1157-9
   PubMed Web of Science ®Google Scholar
• Athyros VG, Ganotakis ES, Elisaf MS, et al.; GREECE-METS Collaborative Group. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 2007;117:204-10
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Kostapanos MS, Liberopoulos EN, et al. Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Int J Clin Pract 2007;61:545-51
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Athyros VG, Kolovou GD, et al. Definitions of metabolic syndrome: where are we now? Curr Vasc Pharmacol 2006;4:185-97
   PubMedGoogle Scholar
• Athyros VG, Bouloukos VI, Pehlivanidis AN, et al.; MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 2005;7:397-405
   PubMed Web of Science ®Google Scholar
• Athyros VG, Ganotakis ES, Bathianaki M, et al.; MetS-Greece Collaborative Group. Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol 2005;46:380-6
   PubMedGoogle Scholar
• International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available at: http://www.idf.org/webdata/docs/MetS_def_update2006.pdf. Accessed 30 Jan 2009
   Google Scholar
• Ford ES, Capewell S. Coronary heart disease mortality among young adults in the US from 1980 through 2002. Concealed leveling of mortality rates. J Am Coll Cardiol 2007;50:2128-32
   PubMed Web of Science ®Google Scholar
• Greenland P, Lloyd-Jones D. Time to end the mixed - and often incorrect - messages about prevention and treatment of atherosclerotic cardiovascular disease. J Am Coll Cardiol 2007;50:2133-5
   PubMed Web of Science ®Google Scholar
• O'Flaherty M, Ford E, Allender S, et al. Coronary heart disease trends in England and Wales from 1984 to 2004: concealed leveling of mortality rates among young adults. Heart 2007; DOI:10.1136/hrt.2007.118323. Available at: http://heart.bmj.com
   PubMedGoogle Scholar
• Bianchi C, Miccoli R, Penno G, et al. Primary prevention of cardiovascular disease in people with dysglycemia. Diabetes Care 2008;31(Suppl 2):208-14
   Google Scholar
• Panagiotakos DB, Pitsavos C, Stefanadis C. Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutr Metab Cardiovasc Dis 2006;16:559-68
   PubMed Web of Science ®Google Scholar
• Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-13
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-9
   PubMed Web of Science ®Google Scholar
• Psaltopoulou T, Orfanos P, Naska A, et al. Prevalence, awareness, treatment and control of hypertension in a general population sample of 26 913 adults in the Greek EPIC study. Int J Epidemiol 2004;33:1345-52
   PubMed Web of Science ®Google Scholar
• Panagiotakos DB, Pitsavos CH, Chrysohoou C, et al. Status and management of hypertension in Greece: role of the adoption of a Mediterranean diet: the Attica study. J Hypertens 2003;21:1483-9
   PubMed Web of Science ®Google Scholar
• Athyros VG, Elisaf M, Mikhailidis DP. Undertreatment of dyslipidaemia in Greece. Atherosclerosis 2004;177:215-16
   PubMed Web of Science ®Google Scholar
• Edelman D, Edwards LJ, Olsen MK, et al. Screening for diabetes in an outpatient clinic population. J Gen Intern Med 2002;17:23-8
   PubMed Web of Science ®Google Scholar
• The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21
   PubMed Web of Science ®Google Scholar
• Unwin N, Shaw J, Zimmet P, et al., for the International Diabetes Federation IGT/IFG Consensus Statement. Report of an Expert Consensus Workshop. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabetic Med 2002;19:708-23
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Temprosa M, Goldberg R, et al.; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611-19
   Google Scholar
• Glueck CJ, Goldenberg N, Sieve L, et al. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. Metabolism 2008;57:954-60
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005;54:1065-74
   PubMed Web of Science ®Google Scholar
• , DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsGerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105
   Google Scholar
• Isoldi KK, Aronne LJ. The challenge of treating obesity: the endocannabinoid system as a potential target. J Am Diet Assoc 2008;108:823-31
   PubMed Web of Science ®Google Scholar
• Pitsavos C, Panagiotakos DB, Chrysohoou C, et al. The adoption of Mediterranean diet attenuates the development of acute coronary syndromes in people with the metabolic syndrome. Nutr J 2003;2:1-5
   PubMed Web of Science ®Google Scholar
• Trichopoulou A, Costacou T, Bamia C, et al. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003;348:2599-608
   PubMed Web of Science ®Google Scholar
• Trichopoulou A, Bamia C, Norat T, et al. Modified Mediterranean diet and survival after myocardial infarction: the EPIC-Elderly study. Eur J Epidemiol 2007;22:871-81
   PubMed Web of Science ®Google Scholar
• Pitsavos C, Panagiotakos DB, Chrysohoou C, et al. The effect of the combination of Mediterranean diet and leisure time physical activity on the risk of developing acute coronary syndromes, in hypertensive subjects. J Hum Hypertens 2002;16:517-24
   PubMed Web of Science ®Google Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, et al. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183-92
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
   Google Scholar
• Athyros VG, Elisaf M, Papageorgiou AA, et al.; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Tzovaras V, Mikhailidis DP, et al. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005;11:4161-75
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Mikhailidis DP, Athyros VG, et al. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin Ther Targets 2007;11:191-205
   PubMed Web of Science ®Google Scholar
• Hoieggen A, Alderman MH, Kjeldsen SE, et al.; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873-83
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-22
   PubMed Web of Science ®Google Scholar